Administration of dietary doses of the isothiocyanate erucin had no effect on rat 2 hepatic cytochrome P450 activity or protein levels, but at higher doses a rise in 3 CYP1A/B1 protein levels was evident. In lung, treatment with erucin, as well as 4 sulforaphane, failed to modulate cytochrome P450 activities but elevated CYP1A/B1 5 protein levels. In liver, erucin stimulated quinone reductase activity accompanied by a 6 rise in protein. Glutathione S-transferase activity was unaffected but GSTα and GSTμ 7 protein levels increased. In lung, both isothiocyanates increased quinone reductase 8 paralleled by a rise in protein levels; at the higher dose both isothiocyanates elevated 9 moderately GSTα levels. Hepatic microsomes converted both isothiocyanates to 10 metabolites that impaired cytochrome P450 activity, which was antagonised by 11 reduced glutathione. It may be concluded that erucin may protect against carcinogens 12 by stimulating the detoxication of quinones but is unlikely to significantly influence 13 reactive intermediate generation through modulation of cytochrome P450 activity. 14 15 16
Isothiocyanates comprise a class of phytochemicals present in cruciferous vegetables 2 and are considered as promising human chemopreventive agents. Epidemiological 3 studies have revealed the potential of these vegetables to protect against a number of 4 cancers (1-3), and indeed individual isothiocyanates have been linked, through 5 epidemiological studies, to lower cancer incidence at a number of sites (4,5). 6
Experimental evidence in animal models supports a chemopreventive role for these 7 chemicals; isothiocyanates can antagonise the carcinogenicity of chemicals, including 8 dietary carcinogens such as polycyclic aromatic hydrocarbons and heterocyclic 9 amines (6,7). Of importance are recent reports that major metabolites of 10 isothiocyanates, such as mercapturates, retain the chemopreventive activity (8). 11
In vegetables isothiocyanates exist in the form of glucosinolates but are 12 released following exposure to the enzyme myrosinase (β-thioglucoside 13 glucohydrolase) which comes into contact with these compounds during the 14 harvesting, chopping and mastication of these vegetables. Moreover, glucosinolates 15 that progress to the human intestine intact may be metabolised by microbial 16 myrosinases, further contributing to the release of isothiocyanates (9). Isothiocyanates 17 are well absorbed and achieve good bioavailability (10). Moreover, experimental 18 evidence has been recently presented that the glucosinolates of isothiocyanates can 19 also be absorbed, at least partly, intact (11). 20
The chemopreventive mechanism of action of isothiocyanates appears to be 21 multifactorial, influencing all stages of chemical carcinogenesis, including 22 impairment of the initiation stage (3,12). Indeed, the consumption of cruciferous 23 vegetables influenced the metabolism of carcinogenic heterocyclic amines in humans 24 (13). One of the most extensively studied isothiocyanate is sulforaphane (1-25 isothiocyanato-4-(methylsulphinyl) butane) (Figure 1 ), encountered at substantial 1 concentrations in broccoli, where it exists as the glucosinolate gluroraphanin. Even 2 when administered at dietary doses, sulforaphane stimulates detoxication enzymes 3 such as quinone reductase (14), and at higher doses it also enhances the activity of 4 other deactivating enzyme systems such as glutathione S-transferase (GST) (15). 5
However, sulforaphane also acts at the post-initiation stages, inducing apoptosis, cell 6 cycle arrest, inhibition of histone deacetylase and suppressing the conversion of lung 7 benign tumours to carcinomas in mice (8,16) .
8
Erucin (1-isothiocyanato-4-(methylthio)-butane) (Figure 1 ) is another 9 isothiocyanate, structurally related to sulforaphane, being its sulphide analogue. It is 10 found as the glucosinolate, glucoerucin, and is a major glucosinolate in rocket salad 11 (roquette; Eruca sativa); moreover there is experimental evidence to suggest that 12 glucoraphanin can be reduced to glucoerucin by mammalian enzymes (11). Erucin 13 itself is also an important metabolite of sulforaphane formed from the reduction of the 14 sulphinyl group; similarly, sulforaphane is a principal metabolite of erucin, generated 15 following sulphur oxidation (11,17). Erucin appears to share many of the biological 16 activities of sulforaphane related to its chemopreventive activity, in many cases being 17 far more potent (18, 19) . 18
Vegetables are usually cooked by boiling, and this procedure results in 19 marked loss of glucosinolates which leach into the cooking water, although other 20 cooking processes such as steaming and microwaving have minimal effects (20) . 21
More importantly, cooking of vegetables denatures myrosinase, the enzyme that 22 converts the glucosinolates to the active isothiocyanates (21). As a result of these two 23 effects, the bioavailabilty of isothiocyanates is drastically decreased. Indeed, the 24 bioavailability of isothiocyanates from broccoli markedly decreased after steaming 25 (Calbiochem, Merck, UK) and antibody to human quinone reductase (abcam 1 Cambridge, UK) were similarly purchased. 2
Male Wistar albino rats (about 180g) were obtained from B&K Universal Ltd 3 (Hull, East Yorkshire, UK). The animals were housed at 22 ± 2 °C, 30-40% relative 4 humidity, in an alternating 12-h light:dark cycle with light onset at 07.00 hr. Rats 5 were randomly divided into four groups, each comprising five animals. One group 6 served as control, two groups were maintained on drinking water containing 30 or 150 7 mg/L erucin, corresponding to approximate daily doses of 3 and 15 mg/kg (18.6 and 8 93.2 μmole/kg) respectively, and the final group was exposed to water containing 9 sulforaphane (150 mg/L, approximate daily dose of 15 mg/kg, i.e. 88.2 μmole/kg); 10 animals were maintained on these regimes for 10 days. At the end of this period, rats 11 were killed by cervical dislocation, livers and lungs were immediately excised, 12 homogenised and post-mitochondrial fractions prepared by centrifugation (9000 g for 13 20 minutes) and stored at -80°C until use. When required, samples were thawed and 14 resolved to microsomal and cytosolic fractions by centrifugation (105 000g x 1 hour). 15
The dealkylations of methoxy-(24), ethoxy-(25), pentoxy-resorufin (26) and 7-16 benzyloxyquinoline (27) were determined using the microsomal fraction. The 17 following assays were performed in the cytosol; quinone reductase using MTT [3-(4,-18 5-dimethylthiazo-2-yl)-2,5-diphenyltetrazolium bromide] as substrate (28), 19 glutathione S-transferase activity using as accepting substrates 1-chloro-2,4-20 dinitrobenzene, 1,2-dichloro-4-nitrobenzene (29) and 7-chloro-4-nitrobenzo-2-oxa-21 1,3-diazole (30), and total glutathione (31). Protein concentration was determined in 22 both fractions using bovine serum albumin as standard (32). Finally, in order to 23 determine changes in enzyme protein expression, hepatic and pulmonary microsomal 24 proteins from pooled animals were resolved by SDS-PAGE before being transferred 25 electrophoretically to Hybond-P polyvinylidene difluoride membrane. Immunoblot 1 analysis was carried out using antibodies to cytochrome P450 or Phase II enzymes, 2 followed by the appropriate peroxidase-labelled secondary antibody. Molecular 3 markers were always run concurrently. Immunoblots were quantitated by 4 densitometry using the GeneTool software (Syngene Corporation, Cambridge, UK). 5
To induce the hepatic CYP1A and CYP2B subfamilies of cytochrome P450, 6 rats were treated with a single intraperitoneal dose of Aroclor-1254 (500 mg/kg), the 7 animals being killed on the 5 th day following administration. In studies aimed at 8 establishing the effect of erucin (25 M) on the in vitro O-dealkylation of 9 ethoxyresorufin, microsomes from Aroclor-1254-induced animals were incubated 10 with erucin or sulforaphane in the presence of NADPH for various periods of time, 11
and reaction was initiated with the addition of the substrate. In studies aimed at 12 studying the concentration-dependent effects, microsomes from Aroclor-1254-13 induced rats were incubated with a series of concentrations of erucin or sulforaphane 14 in the presence of NADPH for 30min, and reaction was initiated with the addition of 15 the substrate. antibodies (Figure 2A) . 14 Cytosolic glutathione S-transferase activity in the liver, determined using 7-15 chloro-4-nitrobenzo-2-oxa-1,3-diazole, 1-chloro-2,4-dinitrobenzene or 1,2-dichloro-4-16 nitrobenzene as substrates, and total glutathione levels were unaffected by the erucin 17 treatment, whereas quinone reductase activity was stimulated at both dose levels 18 (Table 1 ). Immunoblot analysis indicated that erucin, at both dose levels, up-19 regulated the levels of GSTα and GSTμ, as well as quinone reductase, but GST was 20 unaffected ( Figure 2B) . 21
In lung, neither isothiocyanate modulated the O-dealkylation of the two 22 alkoxyresorufins ( Table 2) ; 7-benzyloxyquinoline demethylase was not detectable in 23 this tissue. Immunoblot studies revealed that erucin, at both doses, as well as 24 sulforaphane elevated pulmonary CYP1A1 protein levels ( Figure 3A) . Similarly, the 25 higher erucin dose and sulforaphane increased the band recognised by antibody to 1 CYP1B1 antibody by 80 and 70% respectively ( Figure 3A) . No changes were evident 2 in the case of CYP2B1 or CYP3A2. Glutathione S-transferase activity, whether 3 monitored with 1-chloro-2,4-dinitrobenzene or 7-chloro-4-nitrobenzo-2-oxa-1,3-4 diazole, and total glutathione levels were not influenced by the isothiocyanate 5 treatment. Quinone reductase activity, which was higher in the lung compared with 6 the liver, was clearly elevated by the treatments with erucin or sulforaphane ( Table  7 2). The increase in quinone reductase activity was paralleled by a similar rise in 8 protein levels determined by immunoblot, being 165 and 150% higher in the animals 9 treated with the high erucin dose and sulforaphane respectively, in comparison with 10 controls ( Figure 3B) . Erucin, at the higher dose, similar to sulforaphane, raised the 11 levels of GSTα by 25-30% whereas GST and GSTμ were unaffected ( Figure 2B) . One of the major mechanisms through which isothiocyanates are believed to elicit 5 their anticarcinogenic effects is by limiting the amount of genotoxic metabolites of 6 chemical carcinogens by either stimulating their detoxication and/or impairing their 7 generation (3). Consequently, the aim of this study was to evaluate the potential of the 8 isothiocyanate erucin to modulate glutathione S-transferase and quinone reductase, 9 two pivotal enzymes in the detoxication of reactive intermediates and prevention of 10 oxidative stress, and cytochromes P450, the most important enzyme in the generation 11 of these intermediates; studies were conducted in the liver, the principal site of 12 metabolism, and lung, a target tissue for the anticarcinogenic effect of isothiocyanates 13 (9). The effects of erucin on pulmonary enzymes were compared with those of 14 sulforaphane, as the influence of the latter has not been studied in this tissue following 15 exposure to dietary doses. It has been established that sulforaphane is metabolised to 16 erucin in the rat, and erucin can be readily formed from the reduction of sulforaphane 17 (11, 17) . 18
Previous studies in mice have indicated the potential of erucin and 19 sulforaphane, at least at high doses administered by gavage, to stimulate quinone 20 reductase and glutathione S-transferase activities in the liver and other tissues (23) , 21 but to our knowledge this is the first study evaluating the potential of this 22 isothiocyanate to modulate cytochrome P450 enzymes. Both isothiocyanates were 23
given to rats in the drinking water, and a dose was employed that corresponds to the 24 human intake. Since, to our knowledge, the human consumption levels of erucin or 25 glucoerucin have not been defined, the doses employed in these studies was based on 1 the consumption of sulforaphane, a structurally similar isothiocyanate. A 250g serving 2 of fresh broccoli will release 93-187 mg of sulforaphane (34) , so that the intake for a 3 70 kg individual would be 1.3-2.7 mg/kg. The lower dose of erucin employed in the 4 current study of approximately 3 mg/kg represents such dietary level of intake. 5
None of the cytochrome P450 activities studied were modulated by treatment 6 with erucin in the liver or lung, or with sulforaphane in the lung. In the lung, however, 7 both compounds elevated the levels of the band recognised by the antibody to 8 CYP1A1. CYP1B1 could not be monitored at the activity level as a selective substrate 9
is not available, but immunoblot analysis indicated that treatment with erucin, at the 10 higher dose, elevated the levels of this enzyme in the liver. In the lung, both 11 isothiocyanates led to an increase in the single band detected by the CYP1B1 12 antibody. Neither compound had any effect on CYP2B or CYP3A2 protein levels. 13
Up-regulation of the CYP1 family, albeit at the mRNA level, has been reported 14 following exposure of HepG2 cells to 4-methylthio-3-butenyl isothiocyanate (35). 15
Erucin, at both dose levels, gave rise to a significant increase in hepatic 16 quinone reductase activity as previously described for sulforaphane (14). For both 17 tissues, Western blot analysis indicated that this was due to increased cytosolic 18 concentration of quinone reductase. Contrary to the present observations, exposure of 19 rats to phenethyl isothiocyanate failed to enhance this activity in the lung (36), 20 highlighting the importance of the side chain; it is of interest that sulforaphane and 21 erucin have an aliphatic side chain whereas in the case of phenethyl isothiocyanate it 22 is aromatic. Glutathione S-transferase activity was monitored using three substrates; 23 1-chloro-2,4-dinitrobenzene is a substrate for a number of the cytosolic transferases 24 (37). The much higher activity in the liver compared with the lung reflects the higher 25 capacity of the former tissue to detoxicate electrophiles. Both compounds failed to 1 influence activity in lung and, similarly, in the liver erucin had no effect. 1,2-2 Dichloro-4-nitrobenzene is a substrate associated with the μ-family, but no activity 3 was detectable in lung a as a result of poor expression in this tissue (37). Hepatic 4 activity was not influenced by erucin treatment although a rise in protein levels was 5 clearly visible. Finally, 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole has been reported to 6 be selective for the α-class (30), and the very low activity in the lung demonstrates the 7 poor expression of this class in this tissue (37). A rise in GST activity was not seen 8 with any of the three accepting substrates studied, whereas GSTα and GSTμ were up-9 regulated at the protein level. Similarly, in lung no change in activity was manifested 10 by treatment with either isothiocyanate, but GSTα levels increased, GST was not 11 modulated by either isothiocyanate in either tissue. Thus, the effects of 12 isothiocyanates on the GST system are both compound and tissue specific. 13
As isothiocyanates, with either aliphatic or aromatic side chain, can be 14 metabolically converted to intermediates that cause cytochrome P450 inhibition, the 15 ability of erucin to act as a mechanism-based inhibitor was evaluated and compared to 16 sulforaphane. The two isothiocyanates did not differ in their ability to suppress, in a 17 time-dependent manner, the O-deethylation of ethoxyresorufin. The fact that 18 inhibition was prevented by reduced, but not oxidised, glutathione concords with the 19 generation of an electrophilic metabolite(s). A more reactive isocyanate, derived from 20 the cytochrome P450-mediated isothiocyanate oxidation (38), has been postulated as 21 the possible entity that interacts and inactivates cytochromes P450. Isocyanates are 22 known to be capable of modifying proteins. Indeed, α-naphthyliosothiocyanate was 23 converted by rat liver microsomes, in the presence of NADPH, to metabolites that 24 bound irreversibly to microsomal proteins (39). 25
In order to assess whether the erucin treatment had any impact on the ability of 1 liver microsomes to bioactivate chemical carcinogens, the metabolic conversion of the 2 heterocyclic amine 2-amino-3-methylimidazo-(4,5-f)quinoline (IQ) to mutagens was 3 investigated using the Ames mutagenicity assay. This compound was used as model 4 carcinogen as previous studies showed that sulforaphane inhibits the genotoxicity and 5 DNA-adduct formation of heterocyclic amines in cell cultures in vitro (40,41). Erucin 6 treatment caused a modest decrease in the bioactivation of IQ but no clear 7 concentration-dependent effect was evident. Sulforaphane had a similar, modest effect 8 as we previously reported (14). 9
In summary, the present studies have demonstrated that following intake of 10 erucin, at a dose corresponding to human intake, the only enzyme modulated of those 11 studied was quinone reductase; an increase was seen in both liver and lung. No 12 cytochrome P450 enzyme was perturbed by the erucin treatment implying that 13 attenuated generation of genotoxic intermediates is unlikely to be a chemopreventive 14 mechanism at dietary dose levels. These observations allow us to conclude that erucin 15 may exert a chemopreventive effect by affording protection against the 16 carcinogenicity of quinones, such as those formed by the oxidation of polycyclic 17 aromatic hydrocarbons. At higher doses, which may be achieved by the consumption 18 of dietary supplements, the expression of other enzymes was modulated, at least at the 19 protein level. In general, no marked differences were observed between erucin and 20 sulforaphane. However, as the major source of erucin is rocket salad which is largely 21 consumed uncooked, it may prove a more promising chemopreventive agent than 22 sulforaphane as it is likely to achieve a higher bioavailability. The principal sources of 23 sulforaphane are vegetables which are consumed cooked, resulting in lower 24 conversion of the glucosinolate to the isothiocyanate. Finally, to our knowledge, this 25 is the first paper to report the ability of dietary isothiocyanates to up-regulate CYP1B1 1 expression in the liver and lung. 19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46 2  Figure 2  3  4  5  6  7  A  B  8  9  10   11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34 13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49 17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38 1  Figure 6  2  3  4  5  6  7  8   9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27   0  50  100  250  500  750  1000 
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